Dr.Jian Ge EVP of Preclinical Research Division of Medicilon
Dr. Jian Ge holds a Ph.D. in Neuroscience from the University of Bradford, UK, and a Bachelor’s degree in Pharmacology from the China Pharmaceutical University. He is recognized as a national high-level talent and has served as a professor at Huazhong University of Science and Technology and Wuhan University of Technology. Dr. Ge is also a board member of the Chinese Society of Neuropsychopharmacology and the Anesthesiology Pharmacology Committee of the Chinese Pharmacological Society. He also serves as a review expert for China’s National Major Science and Technology Projects.
Dr. Ge has gained over 30 years experience in drug discovery, with significant achievements in CNS, cardiovascular, metabolic, autoimmune, and oncology diseases. He is proficient in the NMPA/FDA regulatory requirements for IND and NDA applications. Before joining Medicilon, Dr. Ge worked at top global academic institutions and pharmaceutical companies, including the University of Birmingham, the University of Bristol, and Schering-Plough’s UK R&D Center. He has published over 70 academic papers and holds more than 30 patents. He has also led the drug discovery teams at companies such as Hengrui Pharma, Qirui Pharma, and Zhejiang Huahai Pharma, successfully completing multiple IND and NDA applications for both the US and China and advancing over 30 innovative drug projects.In recent years, Medicilon has expanded its capabilities in new molecular drug development, such as nucleic acids, ADCs, PROTACs, antibodies, peptides, vaccines, and cell and gene therapies. Dr. Ge’s appointment aims to drive continuous innovation and enhance Medicilon’s core competitiveness in providing international-standard services.
Dr. Jian Ge, EVP of Preclinical Research Division
” Medicilon’s forward-looking approach in preclinical drug R&D is impressive, especially in nucleic acids, ADCs, PROTACs and antibodies. I am honored to join Medicilon and looking forward to working with the team to empower more innovative therapies to move into clinical trials.”
Dr. Chunlin Chen, Founder, Chairman and CEO of Medicilon
” Dr. Ge’s deep expertise in CNS, cardiovascular, metabolic, and oncology drug development is highly synergistic with Medicilon’s technology platform. His outstanding capabilities in innovative drug R&D and international standards will strengthen our ability to deliver competitive preclinical solutions worldwide.”
About Medicilon
From its inception in 2004, Shanghai Medicilon Inc. (stock code: 688202.SH) has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. By the end of 2024, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 520 new drugs and generic drug projects that have been approved for clinical trials with IND applications.
